The Effect of Selective Laser Trabeculoplasty on Intraocular Pressure in Patients with Dexamethasone Intravitreal Implant-Induced Elevated Intraocular Pressure. (13th October 2020)

• Record Type: Journal Article
• Authors: Bennedjai, Amin; Theillac, Vincent; Akesbi, Jad; Adam, Raphaël; Rodallec, Thibaut; Keilani, Chafik; Blumen-Ohana, Esther; Labbé, Antoine; Nordmann, Jean-Philippe
• Other Names: Santiago Ana Raquel Academic Editor.
• Is Part Of: Journal of ophthalmology. Volume 2020(2020)
• Publication Date: 2020-10-13
• Subjects: Ophthalmology -- Periodicals; Eye Diseases; Ophthalmology; Ophthalmology; Electronic journals; Periodicals; Periodicals; Fulltext; Internet Resources; Periodicals; 617.7
• DOI: 10.1155/2020/3439182
• Languages: English
• ISSNs: 2090-004X

Abstract

Abstract : Introduction . To assess the safety and efficacy of selective laser trabeculoplasty (SLT) for ocular hypertension (OHT) induced by a dexamethasone (DEX) intravitreal implant. Materials and Methods . We performed a retrospective study of patients who underwent an SLT procedure for ocular hypertension induced by injection of a DEX intravitreal implant. Patients had, at least, one injection of the DEX-implant for symptomatic macular edema. SLT was delivered to 360° of the trabecular meshwork in two sessions. The primary outcome was a decrease in IOP, evaluated at one, three, and six months after the SLT procedure. Results . Twenty-six eyes of 22 patients were included. The mean intraocular pressure (IOP) measured after DEX-implant injection was 25.4 ± 5.4 mmHg, and the mean increase in IOP was 35.8 ± 14.6%. The mean follow-up after SLT was 18.3 ± 7.7 months. After SLT, the mean IOP dropped by 30.9% at one month (16.9 ± 4.5 mmHg, p = 0.01 ), 33.6% at three months (16.0 ± 2.7 mmHg, p < 0.01 ), and 34.9% at six months (15.6 ± 2.1 mmHg, p < 0.01 ). Each patient had a minimum follow-up of 6 months after SLT. Eight eyes (31%) received a second DEX-implant injection after the SLT procedure without experiencing an increase in the IOP above 21 mmHg or >20%. No glaucoma surgery was required during the follow-up. The mean number of medications (1.65 ± 1.36) was significantly reduced at one (1.19 ± 1.20, p = 0.04 ), three (0.96 ± 1.03, p < 0.01 ), and six months (0.77 ± 0.95, p < 0.01 ) after SLT. Conclusion . SLT is an effective and safe procedure to control OHT following DEX-implant intravitreal injection.